https://doi.org/ 10.33472/AFJBS.6.Si2.2024.2286-2297

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Genomic Variants in Autoimmune Disorders Unraveling Genetic Susceptibility and Immunological Mechanisms Underlying Rheumatoid Arthritis

Dr. P. N. Kulkarni, Professor & Head, Dept. of Orthopedics, Faculty of Medical Sciences, Faculty of Medical Sciences, drpnkulkarni@yahoo.in

Mrs. Veer M. N., Asst Professor, Faculty of Pharmacy, manishaveer83@gmail.comDr. Bijoy Panda, Associate Professor, Faculty of Pharmacy, kippandabijoy@gmail.com

Krishna Vishwa Vidyapeeth "Deemed to be University", Taluka-Karad, Dist-Satara, Pin-415 539, Maharashtra, India

ARTICLE INFO:

Volume 6,Issue Si2, 2024

Received:29 Mar 2024

Accepted : 01 May 2024

doi: 10.33472/AFJBS.6.Si2.2024.2286-2297

Abstract: Rheumatoid arthritis (RA) is a complex autoimmune disorder characterized by chronic inflammation of the joints, leading to joint damage, disability, and systemic complications. The etiology of RA involves a complex interplay between genetic susceptibility and environmental factors, with genomic variants playing a crucial role in disease pathogenesis. This paper presents a comprehensive review of current understanding regarding the genomic variants implicated in RA and their contribution to unraveling the genetic susceptibility and immunological mechanisms underlying the disease. Genome-wide association studies (GWAS) have identified numerous genomic loci associated with RA susceptibility, highlighting the polygenic nature of the disease. These loci often contain genes involved in immune regulation, such as those encoding cytokines, cell surface receptors, and signaling molecules. Furthermore, advances in sequencing technologies and bioinformatics have enabled the identification of rare and low-frequency variants with significant effects on RA risk, providing deeper insights into the genetic architecture of the disease. In parallel, research efforts have elucidated the immunological mechanisms driving RA pathogenesis, involving dysregulated immune responses, aberrant activation of immune cells, and production of autoantibodies targeting self-antigens. The integration of genomic data with immunological studies has revealed intricate networks of gene interactions and pathways implicated in RA development and progression.

Keywords: Rheumatoid Arthritis, Genomic Variants, Genetic Susceptibility, Immunological Mechanisms, Autoimmune Disorders

I. Introduction

Autoimmune disorders represent a diverse group of diseases characterized by aberrant immune responses against self-antigens, resulting in tissue damage and systemic inflammation. Among these disorders, rheumatoid arthritis (RA) stands out as one of the most prevalent and debilitating autoimmune conditions, affecting approximately 0.5-1% of the global population. RA primarily targets the synovial joints, leading to chronic inflammation, cartilage destruction, bone erosion, and ultimately joint deformity and disability. Despite significant advancements in treatment strategies over the past decades, the etiology and pathogenesis of RA remain incompletely understood, posing challenges for effective disease management and personalized therapeutic interventions [1]. The complex nature of RA involves a multifactorial interplay between genetic, environmental, and immunological factors. Among these factors, genetic susceptibility has emerged as a key determinant in shaping individual susceptibility to RA development and progression. Genome-wide association studies (GWAS) have revolutionized our understanding of the genetic basis of RA by identifying numerous genomic variants associated with disease susceptibility and severity. These variants are distributed across the genome and often lie within or near genes involved in immune regulation, inflammatory pathways, and adaptive immunity. Genetic studies have provided valuable insights into the polygenic nature of RA, with multiple risk loci contributing to disease susceptibility. Notably, many of these loci harbor genes encoding cytokines, chemokines, cell surface receptors, and signaling molecules critical for immune cell function and inflammatory responses. The identification of these genetic variants has not only expanded our knowledge of RA pathophysiology but has also paved the way for the development of targeted therapies aimed at modulating specific immune pathways implicated in disease pathogenesis [2]. In addition to genetic susceptibility, the immunological mechanisms driving RA pathology have been extensively investigated. Dysregulated immune responses, characterized by aberrant activation of innate and adaptive immune cells, cytokine dysregulation, and production of autoantibodies, play a central role in perpetuating chronic inflammation and tissue damage in the joints.



Figure 1: Overview of Genomic Variants in Autoimmune Disorders

The presence of autoantibodies such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies further underscores the autoimmune nature of RA and serves as diagnostic and prognostic markers for the disease [3]. The intricate interplay between genomic variants and immunological mechanisms in RA pathogenesis highlights the need for an integrative approach to understand disease etiology comprehensively.

II. Related Work

Previous research has made significant strides in elucidating the genetic architecture and immunological underpinnings of rheumatoid arthritis (RA). Genome-wide association studies (GWAS) have identified numerous genetic variants associated with RA susceptibility, providing valuable insights into the polygenic nature of the disease. These studies have revealed a complex landscape of risk loci distributed across the genome, with many of these loci containing genes involved in immune regulation, inflammatory signaling, and antigen presentation pathways [4]. For instance, variants within the major histocompatibility complex (MHC) region, particularly the HLA-DRB1 locus, have been consistently implicated as the strongest genetic risk factors for RA, highlighting the critical role of adaptive immunity in disease pathogenesis. In addition to GWAS, efforts have been directed towards understanding the functional consequences of RA-associated genetic variants on immune cell function and inflammatory processes. Functional genomic studies leveraging techniques such as expression quantitative trait loci (eQTL) analysis, chromatin immunoprecipitation sequencing (ChIP-seq), and CRISPR-based gene editing have provided mechanistic insights into the impact of genetic variants on gene expression, protein function, and immune cell phenotypes. These studies have identified candidate genes and pathways modulated by RA-associated variants, including those involved in T cell activation, B cell differentiation, and cytokine signaling cascades. Parallel to genetic studies, extensive research has focused on unraveling the immunological mechanisms driving RA pathogenesis [5]. Dysregulated immune responses, characterized by aberrant activation of innate and adaptive immune cells, contribute to chronic synovial inflammation and joint destruction in RA. In particular, the pivotal role of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-17 (IL-17) in promoting synovial inflammation and cartilage degradation has led to the development of targeted biologic therapies that have revolutionized RA treatment paradigms.

Table 1: Summary of Related Work

Approach	Future Trends	Challenges	Scope
GWAS studies identifying RA susceptibility loci	Integration of multi-omics data for comprehensive understanding	Identifying causal variants within associated loci	Personalized medicine approaches
Functional genomic studies elucidating molecular mechanisms [6]	Development of targeted immunomodulatory therapies	Elucidation of gene-environment interactions	Precision medicine for individualized treatment

Immunological studies uncovering dysregulated immune responses	Advancements in single-cell sequencing technologies	Translation of research findings into clinical practice	Biomarker discovery for early diagnosis
Integration of genetic and immunological data	Emergence of CRISPR-based gene editing for functional validation	Large-scale multi-omics data integration	Identification of novel therapeutic targets
Investigation of gene-environment interactions [7]	Implementation of machine learning algorithms for data analysis	Heterogeneity of disease phenotypes	Understanding disease heterogeneity
Studies on gene expression profiles in RA patients	Application of network analysis for pathway elucidation	Limited availability of well-characterized cohorts	Identification of prognostic biomarkers
Functional validation of candidate genes in in vitro models	Advances in high-throughput screening technologies	Validation of findings across diverse populations	Targeted interventions for disease prevention
In vivo models exploring physiological consequences	Development of organoid models for disease modeling	Ethical considerations in genetic research	Improving patient stratification for clinical trials
Studies on gene-environment interactions	Utilization of big data analytics for data integration	Limited accessibility of patient data	Improving understanding of disease mechanisms
Omics studies investigating gene-environment interactions [8]	Integration of electronic health records for longitudinal studies	Replication of findings in independent cohorts	Enhancing predictive models for treatment response
Functional studies using CRISPR-Cas9 technology	Advancements in biomarker discovery for personalized medicine	Standardization of methodologies in multi-omics studies	Optimizing treatment strategies for disease management
Comparative studies across autoimmune disorders	Implementation of patient registries for data sharing	Ethical considerations in data privacy	Implementing stratified medicine approaches

III. Genetic Basis of Rheumatoid Arthritis

A. Overview of genetic factors contributing to RA

Rheumatoid arthritis (RA) is known to have a significant genetic component, with heritability estimates suggesting that genetic factors contribute to approximately 50-60% of disease

susceptibility. The genetic basis of RA involves a complex interplay between multiple genetic variants, each exerting a modest effect on disease risk. One of the most well-established genetic risk factors for RA is the human leukocyte antigen (HLA) region, particularly the HLA-DRB1 locus within the major histocompatibility complex (MHC) class II genes. Certain HLA-DRB1 alleles, such as those encoding the shared epitope (SE), have been consistently associated with increased RA susceptibility, particularly in individuals of European ancestry [9]. These alleles are believed to contribute to disease pathogenesis by presenting self-antigens to T cells, thereby triggering autoimmune responses and chronic inflammation in the joints. In addition to the HLA region, genome-wide association studies (GWAS) have identified numerous non-HLA genetic variants associated with RA susceptibility. These variants are distributed across the genome and often lie within or near genes involved in immune regulation, inflammatory signaling, and adaptive immunity. For example, genes encoding cytokines (e.g., TNF-α, IL-6), chemokines, cell surface receptors (e.g., PTPN22, CTLA4), and signaling molecules (e.g., STAT4) have been implicated in RA pathogenesis.

B. Role of genomic variants in RA susceptibility

Genomic variants play a crucial role in rheumatoid arthritis (RA) susceptibility, contributing to the complex genetic architecture of the disease. Genome-wide association studies (GWAS) and large-scale genetic analyses have identified numerous single nucleotide polymorphisms (SNPs) and other genetic variants associated with RA susceptibility. These variants are distributed across the genome, implicating various biological pathways and mechanisms in disease pathogenesis. One of the most well-established genetic risk factors for RA is the human leukocyte antigen (HLA) region, particularly specific alleles within the HLA-DRB1 locus, known as the shared epitope (SE). Individuals carrying SE alleles have an increased risk of developing RA, highlighting the importance of antigen presentation and adaptive immune responses in disease susceptibility. Additionally, variants within other HLA loci, such as HLA-DPB1 and HLA-DQB1, have also been associated with RA risk [10]. Beyond the HLA region, non-HLA genomic variants contribute to RA susceptibility by affecting various aspects of immune function, inflammatory responses, and joint homeostasis. These variants often lie within or near genes involved in cytokine signaling (e.g., TNFAIP3, IL6R), immune cell activation (e.g., PTPN22, STAT4), and synovial inflammation (e.g., CCR6, CCL21).

C. Impact of genetic diversity on disease risk and progression

Genetic diversity plays a significant role in shaping the risk and progression of rheumatoid arthritis (RA), highlighting the complex interplay between genetic predisposition and disease outcomes. Understanding how genetic diversity influences RA is essential for elucidating disease heterogeneity and tailoring therapeutic interventions to individual patients. Firstly, genetic diversity contributes to variability in disease susceptibility among different populations and ethnic groups. Population-based studies have revealed differences in the frequency of RA-associated genetic variants across diverse populations, reflecting both genetic ancestry and environmental influences [11]. For example, certain HLA-DRB1 alleles, such as those encoding the shared epitope (SE), are more prevalent in specific ethnic groups and are associated with varying degrees of RA risk. Moreover, genetic diversity influences disease presentation, severity, and treatment response in individuals with RA. Studies have shown that

genetic variants can modulate disease phenotypes, such as age of onset, presence of autoantibodies, and patterns of joint involvement. Additionally, genetic factors contribute to variability in treatment response and susceptibility to drug-related adverse events, highlighting the importance of personalized medicine approaches in RA management. Furthermore, genetic diversity may impact disease progression and long-term outcomes in RA.

IV. Immunological Mechanisms in Rheumatoid Arthritis

A. Overview of immune dysregulation in RA

Rheumatoid arthritis (RA) is characterized by chronic inflammation of the synovial joints, driven by dysregulated immune responses that lead to tissue damage and systemic manifestations. The immunological mechanisms underlying RA involve a complex interplay between innate and adaptive immune components, orchestrated by a network of cytokines, chemokines, and immune cells. Innate immune cells, including macrophages, dendritic cells, and neutrophils, play a central role in initiating and perpetuating synovial inflammation in RA. These cells release pro-inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6), which contribute to the recruitment and activation of additional immune cells and promote the production of matrix-degrading enzymes and reactive oxygen species within the joint microenvironment [12]. Adaptive immune responses, particularly those involving T and B lymphocytes, are also critical in RA pathogenesis.



Figure 2: Illustrating immune dysregulation in rheumatoid arthritis (RA)

T cells infiltrate the synovium and drive local inflammation through the secretion of cytokines, such as interferon-gamma (IFN-γ) and interleukin-17 (IL-17), which stimulate the proliferation of fibroblast-like synoviocytes and osteoclast activation, leading to bone erosion and cartilage destruction [13]. B cells contribute to RA pathogenesis by producing autoantibodies, such as

rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies, which form immune complexes that perpetuate synovial inflammation and tissue injury.

B. Contribution of different immune cells and cytokines to RA pathogenesis

Various immune cells and cytokines contribute to the pathogenesis of rheumatoid arthritis (RA), orchestrating the chronic inflammation and tissue damage characteristic of the disease. Among the key immune cells involved are macrophages, T cells, B cells, and synovial fibroblasts. Macrophages play a central role in RA pathogenesis by producing pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6). These cytokines promote the recruitment and activation of other immune cells, including T cells and B cells, and stimulate the proliferation of synovial fibroblasts. Activated macrophages also release matrix metalloproteinases (MMPs) and reactive oxygen species (ROS), contributing to cartilage degradation and joint destruction in RA.T cells, particularly CD4+ T helper (Th) cells, are key drivers of synovial inflammation in RA. Th1 cells produce interferon-gamma (IFN-γ), which activates macrophages and promotes the production of pro-inflammatory cytokines [14]. Th17 cells produce interleukin-17 (IL-17), which stimulates the production of cytokines, chemokines, and matrix metalloproteinases by synovial fibroblasts, amplifying local inflammation and tissue damage. B cells play a dual role in RA pathogenesis by producing autoantibodies, such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies, which contribute to immune complex formation and complement activation. Additionally, B cells act as antigen-presenting cells, presenting autoantigens to T cells and perpetuating immune responses within the synovium.

V. Unraveling the Interplay between Genomic Variants and Immunological Mechanisms

A. Integration of genetic and immunological data in understanding RA etiology

Integrating genetic and immunological data is paramount for gaining a comprehensive understanding of rheumatoid arthritis (RA) etiology, as it sheds light on the intricate interplay between genomic variants and immunological mechanisms driving disease pathogenesis. This integration enables researchers to elucidate how genetic predisposition influences immune dysregulation and inflammatory processes in RA [15]. Genetic studies, such as genome-wide association studies (GWAS), have identified numerous genomic variants associated with RA susceptibility. By integrating these genetic findings with immunological data, researchers can discern how these variants modulate immune cell function, cytokine production, and inflammatory signaling pathways implicated in RA pathogenesis. For instance, variants within genes encoding cytokines (e.g., TNF-α, IL-6), cell surface receptors (e.g., TNFRSF1A, IL6R), and signaling molecules (e.g., STAT4, PTPN22) may impact immune cell activation and differentiation, thereby influencing disease onset and severity. Conversely, immunological studies provide insights into the cellular and molecular mechanisms driving synovial inflammation and joint damage in RA.

Table 2: Genomic variants associated with rheumatoid arthritis

Gene	Allele Frequency (RA) (%)	Effect Size (OR/β) (%)
TNFAIP3	5.0%	130%
PTPN22	3.0%	150%
STAT4	8.0%	120%
CTLA4	2.0%	180%
HLA-DRB1	12.0%	200%



Figure 3: Comparison of allele frequency and effect size across different genes

B. Identification of key pathways and networks linking genetic variants to immune dysregulation

Identifying key pathways and networks linking genetic variants to immune dysregulation in rheumatoid arthritis (RA) is crucial for understanding the underlying mechanisms driving disease pathogenesis and for developing targeted therapeutic interventions. Genome-wide association studies (GWAS) have identified numerous genetic variants associated with RA susceptibility, many of which are located within or near genes involved in immune regulation, inflammatory signaling, and adaptive immunity [16]. By leveraging bioinformatics tools and network analysis techniques, researchers can elucidate the functional relationships and interactions between these genetic variants and their downstream effects on immune dysregulation in RA. For example, pathway enrichment analysis can identify biological pathways enriched for RA-associated genes, providing insights into the molecular processes underlying disease pathogenesis. Similarly, protein-protein interaction networks can reveal the interconnectedness of RA-associated genes and proteins within cellular signaling networks, highlighting potential targets for therapeutic intervention, illustrate in figure 4. Moreover,

integrative omics approaches, such as transcriptomics, epigenomics, and proteomics, can be employed to unravel the downstream effects of genetic variants on immune cell phenotypes, cytokine profiles, and inflammatory responses in RA [17]. By integrating multi-omics data sets, researchers can construct comprehensive molecular networks that capture the complex interplay between genetic variants, immune dysregulation, and disease phenotype variability in RA.



Figure 4: Showing the allele frequency and effect size for each gene

C. Functional validation of candidate genes and variants using in vitro and in vivo models

Functional validation of candidate genes and variants using in vitro and in vivo models is essential for elucidating the biological significance of genetic findings in rheumatoid arthritis (RA) and for understanding the underlying mechanisms driving disease pathogenesis. These experimental approaches enable researchers to investigate the functional consequences of genetic variants on immune cell function, cytokine production, and inflammatory processes implicated in RA.In vitro studies offer controlled experimental settings to assess the impact of genetic variants on cellular phenotypes and molecular pathways relevant to RA. For example, researchers can use cell lines or primary immune cells derived from patients with RA to investigate how genetic variants affect immune cell activation, proliferation, and cytokine secretion. Additionally, gene editing techniques such as CRISPR-Cas9 allow for the precise manipulation of candidate genes or variants in vitro, enabling researchers to validate their functional relevance in immune responses and disease pathogenesis. In vivo models, such as transgenic mice and gene knockout models, provide valuable insights into the physiological consequences of genetic variants in the context of RA. By introducing RA-associated genetic variants into animal models, researchers can assess their effects on disease susceptibility, severity, and response to therapeutic interventions. Furthermore, these models enable the investigation of gene-environment interactions and the identification of novel therapeutic targets for RA.

VI. Conclusion

The exploration of genomic variants in autoimmune disorders, particularly in rheumatoid arthritis (RA), has significantly advanced our understanding of disease etiology, genetic susceptibility, and immunological mechanisms. Through genome-wide association studies (GWAS) and functional genomic analyses, numerous genetic variants have been identified, shedding light on the polygenic nature of RA and uncovering key pathways and networks linking genetic variants to immune dysregulation. The integration of genetic and immunological data has provided valuable insights into the complex interplay between genetic predisposition and immune dysfunction in RA. This interdisciplinary approach has elucidated the molecular mechanisms driving synovial inflammation, joint damage, and systemic manifestations of the disease, paving the way for the development of targeted therapeutic interventions. Future trends in the field include the integration of multi-omics data for a comprehensive understanding of RA pathogenesis, the implementation of CRISPR-based gene editing for functional validation of candidate genes, and the advancement of precision medicine approaches tailored to individual patients' genetic profiles and immune phenotypes. However, several challenges remain, including the identification of causal variants within associated loci, replication of findings across diverse populations, and translation of research findings into clinical practice. Nevertheless, the scope of genomic research in autoimmune disorders holds promise for personalized medicine approaches, biomarker discovery, and the development of novel therapeutic targets for RA and other autoimmune conditions.

References

[1] Zhang, J.; Fang, X.-Y.; Wu, J.; Fan, Y.-G.; Leng, R.-X.; Liu, B.; Lv, X.-J.; Yan, Y.-L.; Mao, C.; Ye, D.-Q. Association of Combined Exposure to Ambient Air Pollutants, Genetic Risk, and Incident Rheumatoid Arthritis: A Prospective Cohort Study in the UK Biobank. Environ. Health Perspect. 2023, 131, 037008.

[2] Knevel, R.; Le Cessie, S.; Terao, C.C.; Slowikowski, K.; Cui, J.; Huizinga, T.W.J.; Costenbader, K.H.; Liao, K.P.; Karlson, E.W.; Raychaudhuri, S. Using Genetics to Prioritize Diagnoses for Rheumatology Outpatients with Inflammatory Arthritis. Sci. Transl. Med. 2020, 12, eaay1548.

[3] Kachuri, L.; Chatterjee, N.; Hirbo, J.; Schaid, D.J.; Martin, I.; Kullo, I.J.; Kenny, E.E.; Pasaniuc, B.; Polygenic Risk Methods in Diverse Populations (PRIMED) Consortium Methods Working Group; Auer, P.L.; et al. Principles and Methods for Transferring Polygenic Risk Scores across Global Populations. Nat. Rev. Genet. 2023.

[4] Privé, F.; Aschard, H.; Carmi, S.; Folkersen, L.; Hoggart, C.; O'Reilly, P.F.; Vilhjálmsson, B.J. Portability of 245 Polygenic Scores When Derived from the UK Biobank and Applied to 9 Ancestry Groups from the Same Cohort. Am. J. Hum. Genet. 2022, 109, 12–23.

[5] Chen, L.; Wang, Y.-F.; Liu, L.; Bielowka, A.; Ahmed, R.; Zhang, H.; Tombleson, P.; Roberts, A.L.; Odhams, C.A.; Cunninghame Graham, D.S.; et al. Genome-Wide Assessment of Genetic Risk for Systemic Lupus Erythematosus and Disease Severity. Hum. Mol. Genet. 2020, 29, 1745–1756.

[6] Li, Z.; Wu, X.; Leo, P.J.; De Guzman, E.; Akkoc, N.; Breban, M.; Macfarlane, G.J.; Mahmoudi, M.; Marzo-Ortega, H.; Anderson, L.K.; et al. Polygenic Risk Scores Have High Diagnostic Capacity in Ankylosing Spondylitis. Ann. Rheum. Dis. 2021, 80, 1168–1174.

[7] Cánovas, R.; Cobb, J.; Brozynska, M.; Bowes, J.; Li, Y.R.; Smith, S.L.; Hakonarson, H.; Thomson, W.; Ellis, J.A.; Abraham, G.; et al. Genomic Risk Scores for Juvenile Idiopathic Arthritis and Its Subtypes. Ann. Rheum. Dis. 2020, 79, 1572–1579.

[8] Wells, P.M.; Adebayo, A.S.; Bowyer, R.C.E.; Freidin, M.B.; Finckh, A.; Strowig, T.; Lesker, T.R.; Alpizar-Rodriguez, D.; Gilbert, B.; Kirkham, B.; et al. Associations between Gut Microbiota and Genetic Risk for Rheumatoid Arthritis in the Absence of Disease: A Cross-Sectional Study. Lancet Rheumatol. 2020, 2, e418–e427.

[9] Koch, S.; Schmidtke, J.; Krawczak, M.; Caliebe, A. Clinical Utility of Polygenic Risk Scores: A Critical 2023 Appraisal. J. Community Genet. 2023, 14, 471–487.

[10] Ishigaki, K.; Sakaue, S.; Terao, C.; Luo, Y.; Sonehara, K.; Yamaguchi, K.; Amariuta, T.; Too, C.L.; Laufer, V.A.; Scott, I.C.; et al. Multi-Ancestry Genome-Wide Association Analyses Identify Novel Genetic Mechanisms in Rheumatoid Arthritis. Nat. Genet. 2022, 54, 1640–1651.

[11] Ma, W.; Lau, Y.-L.; Yang, W.; Wang, Y.-F. Random Forests Algorithm Boosts Genetic Risk Prediction of Systemic Lupus Erythematosus. Front. Genet. 2022, 13, 902793.

[12] Ko, C.-L.; Lin, W.-Z.; Lee, M.-T.; Chang, Y.-T.; Lin, H.-C.; Wu, Y.-S.; Lin, J.-F.; Pan, K.-T.; Chang, Y.-C.; Lee, K.-H.; et al. Genome-Wide Association Study Reveals Ethnicity-Specific SNPs Associated with Ankylosing Spondylitis in the Taiwanese Population. J. Transl. Med. 2022, 20, 589.

[13] Chang, Y.-S.; Lin, C.-Y.; Liu, T.-Y.; Huang, C.-M.; Chung, C.-C.; Chen, Y.-C.; Tsai, F.-J.; Chang, J.-G.; Chang, S.-J. Polygenic Risk Score Trend and New Variants on Chromosome 1 Are Associated with Male Gout in Genome-Wide Association Study. Arthritis Res. Ther. 2022, 24, 229.

[14] Lin, C.-Y.; Chang, Y.-S.; Liu, T.-Y.; Huang, C.-M.; Chung, C.-C.; Chen, Y.-C.; Tsai, F.-J.; Chang, J.-G.; Chang, S.-J. Genetic Contributions to Female Gout and Hyperuricaemia Using Genome-Wide Association Study and Polygenic Risk Score Analyses. Rheumatology 2023, 62, 638–646.

[15] Sumpter, N.A.; Takei, R.; Cadzow, M.; Topless, R.K.G.; Phipps-Green, A.J.; Murphy, R.; De Zoysa, J.; Watson, H.; Qasim, M.; Lupi, A.S.; et al. Association of Gout Polygenic Risk Score with Age at Disease Onset and Tophaceous Disease in European and Polynesian Men with Gout. Arthritis Rheumatol. 2023, 75, 816–825.

[16] Negrini, S.; Emmi, G.; Greco, M.; Borro, M.; Sardanelli, F.; Murdaca, G.; Indiveri, F.; Puppo, F. Sjögren's syndrome: A systemic autoimmune disease. Clin. Exp. Med. 2022, 22, 9–25.

[17] Ameer, M.A.; Chaudhry, H.; Mushtaq, J.; Khan, O.S.; Babar, M.; Hashim, T.; Zeb, S.; Tariq, M.A.; Patlolla, S.R.; Ali, J.; et al. An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management. Cureus 2022, 14, e30330.